{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:50:19Z","timestamp":1788367819681,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007950","name":"Tanta University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007950","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Axial spondyloarthritis (axSpA) is chronic autoimmune disease affecting axial skeleton. Recently autoantibodies against CD74 have been linked to the pathogenesis of axSpA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Investigate the diagnostic value of anti-CD74 in Egyptian axSpA patients and their relation to disease activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included 30 axSpA patients and control groups, which included 30 patients with peripheral psoriatic arthritis, and 30 healthy volunteers. disease activity was assessed using ASDAS-CRP (Ankylosing Spondylitis Disease Activity Score) and BASDAI (bath ankylosing spondylitis disease activity index) for axSpA patients. Bath ankylosing spondylitis functional index (BASFI) was used for functional assessment and mobility was assessed using Bath Ankylosing Spondylitis Metrology Index (BASMI). ESR, CRP and serum anti-CD74 IgA were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There was no significant difference between the three studied groups regarding sex, age, and BMI. The serum levels of anti-CD74 IgA antibodies were significantly higher in axSpA patients compared to control groups.73.3, 66.6 and 3.3% of the axSpA, Peripheral psoriatic arthritis and healthy group, respectively, were anti- CD74 IgA antibody positive. Its specificity was 96.67% compared to the healthy control group, and 33.3% specificity compared to the peripheral psoriatic arthritis group. There was no significant correlation between anti-CD74 IgA antibodies and age, sex, duration of the disease, acute phase reactant, ASDAS-CRP, BASDAI, BASFI, and BASMI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IgA anti-CD74 may be a useful marker for identifying axSpA. Further research on patients with peripheral SpA is required to determine the practical benefits of this biomarker.<\/jats:p>\n                    <jats:table-wrap>\n                      <jats:table>\n                        <jats:tbody>\n                          <jats:tr>\n                            <jats:td colspan=\"2\">\n                              <jats:bold>Key Points<\/jats:bold>\n                              \u2022\n                              <jats:italic>Patients with axSpA had a significantly greater serum level of IgA anti-CD74 than controls<\/jats:italic>\n                              .\u2022\n                              <jats:italic>IgA Anti-CD74 had excellent discriminatory power in distinguishing axSpA from healthy controls but fair discriminatory power in distinguishing axSpA from peripheral psoriatic arthritis<\/jats:italic>\n                              .\u2022\n                              <jats:italic>IgA anti-CD74 wasn\u2019t correlated with acute phase reactant or disease activity<\/jats:italic>\n                              .\n                            <\/jats:td>\n                          <\/jats:tr>\n                        <\/jats:tbody>\n                      <\/jats:table>\n                    <\/jats:table-wrap>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-025-07695-3","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T08:19:55Z","timestamp":1764836395000},"page":"935-943","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-CD74 IgA as a potential biomarker in axial spondyloarthritis: diagnostic utility and clinical implications"],"prefix":"10.1007","volume":"45","author":[{"given":"Gehad Elsayed Mohammed","family":"Ammar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Eed","family":"Eldeeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba Ahmed","family":"Mourad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6414-5602","authenticated-orcid":false,"given":"Samar AbdAlhamed","family":"Tabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"issue":"9783","key":"7695_CR1","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","volume":"377","author":"M Dougados","year":"2011","unstructured":"Dougados M, Baeten D (2011) Spondyloarthritis. Lancet 377(9783):2127\u20132137. https:\/\/doi.org\/10.1016\/S0140-6736(11)60071-8","journal-title":"Lancet"},{"key":"7695_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, S\u00f8rensen IJ, Ozgocmen S, Roussou E, Valle-O\u00f1ate R, Weber U, Wei J, Sieper J (2009) The development of assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777\u2013783. https:\/\/doi.org\/10.1136\/ard.2009.108233","journal-title":"Ann Rheum Dis"},{"key":"7695_CR3","first-page":"2283","volume":"54","author":"MP Sykes","year":"2015","unstructured":"Sykes MP, Doll H, Sengupta R, Gaffney K (2015) Delay to diagnosis in axial spondyloarthritis: are we improving in the UK? Rheumatology 54:2283\u20132284","journal-title":"Rheumatology"},{"issue":"4","key":"7695_CR4","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jbspin.2016.06.005","volume":"84","author":"V Masson Behar","year":"2017","unstructured":"Masson Behar V, Dougados M, Etcheto A, Kreis S, Fabre S, Hudry C, Dadoun S, Rein C, Pertuiset E, Fautrel B, Gossec L (2017) Diagnostic delay in axial spondyloarthritis: a cross-sectional study of 432 patients. Joint Bone Spine 84(4):467\u2013471. https:\/\/doi.org\/10.1016\/j.jbspin.2016.06.005","journal-title":"Joint Bone Spine"},{"issue":"6","key":"7695_CR5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/ard.2009.108217","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Landew\u00e9 R, van der Heijde D, Listing J, Brandt J, Braun J, Burgos-Vargas R, Collantes-Estevez E, Davis J, Dijkmans B, Dougados M, Emery P, van der Horst-Bruinsma IE, Inman R, Khan MA, Leirisalo-Repo M, van der Linden S, Maksymowych WP, Mielants H, Olivieri I, Sturrock R, de Vlam K, Sieper J (2009) The development of assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 68(6):770\u2013776. https:\/\/doi.org\/10.1136\/ard.2009.108217","journal-title":"Ann Rheum Dis"},{"key":"7695_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-immunol-032414-112110","volume":"33","author":"P Bowness","year":"2015","unstructured":"Bowness P (2015) HLA-B27. Annu Rev Immunol 33:29\u201348. https:\/\/doi.org\/10.1146\/annurev-immunol-032414-112110","journal-title":"Annu Rev Immunol"},{"key":"7695_CR7","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3389\/fimmu.2019.01232","volume":"10","author":"M Fiorillo","year":"2019","unstructured":"Fiorillo M, Haroon N, Ciccia F, Breban M (2019) Editorial: ankylosing spondylitis and related immune- mediated disorders. Front Immunol 10:1232. https:\/\/doi.org\/10.3389\/fimmu.2019.01232","journal-title":"Front Immunol"},{"key":"7695_CR8","doi-asserted-by":"publisher","first-page":"5556s","DOI":"10.1158\/1078-0432.CCR-07-1167","volume":"13","author":"R Stein","year":"2007","unstructured":"Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, Govindan S, Goldenberg DM (2007) CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res 13:5556s-s5563. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1167","journal-title":"Clin Cancer Res"},{"issue":"4","key":"7695_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/BOR.0000000000000180","volume":"27","author":"WP Maksymowych","year":"2015","unstructured":"Maksymowych WP (2015) Biomarkers in axial spondyloarthritis. Curr Opin Rheumatol 27(4):343\u2013348. https:\/\/doi.org\/10.1097\/BOR.0000000000000180","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"7695_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s10165-009-0230-9","volume":"20","author":"LD Kozaci","year":"2010","unstructured":"Kozaci LD, Sari I, Alacacioglu A, Akar S, Akkoc N (2010) Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor. Mod Rheumatol 20(1):34\u201339. https:\/\/doi.org\/10.1007\/s10165-009-0230-9","journal-title":"Mod Rheumatol"},{"issue":"10","key":"7695_CR11","doi-asserted-by":"publisher","first-page":"7865","DOI":"10.1074\/jbc.M106020200","volume":"277","author":"S Onodera","year":"2002","unstructured":"Onodera S, Nishihira J, Iwabuchi K, Koyama Y, Yoshida K, Tanaka S, Minami A (2002) Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts. Relevance to intracellular signaling pathways. J Biol Chem 277(10):7865\u20137874. https:\/\/doi.org\/10.1074\/jbc.M106020200","journal-title":"J Biol Chem"},{"issue":"8","key":"7695_CR12","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665\u20132673. https:\/\/doi.org\/10.1002\/art.21972","journal-title":"Arthritis Rheum"},{"issue":"5","key":"7695_CR13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/art.40777","volume":"71","author":"E Riechers","year":"2019","unstructured":"Riechers E, Baerlecken N, Baraliakos X, Achilles-Mehr Bakhsh K, Aries P, Bannert B, Becker K, Brandt-J\u00fcrgens J, Braun J, Ehrenstein B, Euler HH, Fleck M, Hein R, Karberg K, K\u00f6hler L, Matthias T, Max R, Melzer A, Meyer-Olson D, Rech J, Rockwitz K, Rudwaleit M, Schmidt RE, Schweikhard E, Sieper J, Stille C, von Hin\u00fcber U, Wagener P, Weidemann HF, Zinke S, Witte T (2019) Sensitivity and specificity of autoantibodies against CD74 in nonradiographic axial spondyloarthritis. Arthritis Rheumatol 71(5):729\u2013735. https:\/\/doi.org\/10.1002\/art.40777","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"7695_CR14","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","volume":"77","author":"Machado PM, Landew\u00e9 R, Heijde DV, Assessment of SpondyloArthritis international Society (ASAS). Ankylosing Spondylitis Disease Activity Score (ASDAS)","year":"2018","unstructured":"Machado PM, Landew\u00e9 R, Heijde DV, Assessment of SpondyloArthritis international Society (ASAS). Ankylosing Spondylitis Disease Activity Score (ASDAS) (2018) update of the nomenclature for disease activity states. Ann Rheum Dis 77(10):1539\u20131540. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213184","journal-title":"Ann Rheum Dis"},{"key":"7695_CR15","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). J Rheumatol 21:2286\u20132291","journal-title":"J Rheumatol"},{"key":"7695_CR16","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, Kennedy LG, O\u2019Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281\u20132285","journal-title":"J Rheumatol"},{"key":"7695_CR17","doi-asserted-by":"publisher","unstructured":"Zochling J (2011) Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res (Hoboken) ;63 Suppl 11:S47\u201358. https:\/\/doi.org\/10.1002\/acr.20575.","DOI":"10.1002\/acr.20575"},{"key":"7695_CR18","volume-title":"A simple guide to IBM SPSS statistics for version 20.0 student ed","author":"LA Kirkpatrick","year":"2013","unstructured":"Kirkpatrick LA, Feeney BC (2013) A simple guide to IBM SPSS statistics for version 20.0 student ed. Wadsworth, Cengage Learning, Belmont"},{"issue":"1","key":"7695_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13075-018-1535-x","volume":"20","author":"JJ de Winter","year":"2018","unstructured":"de Winter JJ, van de Sande MG, Baerlecken N, Berg I, Ramonda R, van der Heijde D, van Gaalen FA, Witte T, Baeten DL (2018) Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort. Arthritis Res Ther 20(1):38. https:\/\/doi.org\/10.1186\/s13075-018-1535-x","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"7695_CR20","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1093\/rheumatology\/keaa882","volume":"60","author":"L Do","year":"2021","unstructured":"Do L, Gran\u00e5sen G, Hellman U, Lejon K, Geijer M, Baraliakos X, Witte T, Forsblad-d\u2019Elia H (2021) Anti-CD74 IgA autoantibodies in radiographic axial spondyloarthritis: a longitudinal Swedish study. Rheumatology (Oxford) 60(9):4085\u20134093. https:\/\/doi.org\/10.1093\/rheumatology\/keaa882","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"7695_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.20514\/2226-6704-2022-12-4-310-315","volume":"12","author":"AP Rebrov","year":"2022","unstructured":"Rebrov AP, Gaydukova IZ, Aparkina AV, Korolev MA, Safarova KN, Dorogoikina KD, Bichurina DM (2022) The level of IgA antibodies to CD74 in patients with spondyloarthritis and degenerative-dystrophic diseases of the spine. The Russian Archives of Internal Medicine 12(4):310\u2013315. https:\/\/doi.org\/10.20514\/2226-6704-2022-12-4-310-315","journal-title":"The Russian Archives of Internal Medicine"},{"issue":"2","key":"7695_CR22","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/rheumatology\/keac384","volume":"62","author":"AS De Craemer","year":"2023","unstructured":"De Craemer AS, Witte T, Lobaton Ortega T, Hoorens A, De Vos M, Cuvelier C, Vastert SJ, Baraliakos X, Van den Bosch F, Elewaut D (2023) Anti-CD74 IgA antibodies show diagnostic potential for axial spondyloarthritis but are not associated with microscopic gut inflammation. Rheumatology (Oxford) 62(2):984\u2013990. https:\/\/doi.org\/10.1093\/rheumatology\/keac384","journal-title":"Rheumatology (Oxford)"},{"key":"7695_CR23","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3389\/fimmu.2019.00574","volume":"10","author":"NR Ziade","year":"2019","unstructured":"Ziade NR, Mallak I, Merheb G, Ghorra P, Baerlecken N, Witte T, Baraliakos X (2019) Added value of anti- CD74 autoantibodies in axial spondyloarthritis in a population with low HLA-B27 prevalence. Front Immunol 10:574. https:\/\/doi.org\/10.3389\/fimmu.2019.00574","journal-title":"Front Immunol"},{"key":"7695_CR24","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/annrheumdis-2018-eular","volume":"77","author":"I Gaydukova","year":"2018","unstructured":"Gaydukova I, Rebrov A, Maslyanskiy A, Lapin SV, Vasilenko E, Mazurov V (2018) Diagnostic value of anti-CD74 autoantibodies in axial spondyloarthritis and axial psoriatic arthritis results of open-label, cross-sectional, controlled, multicenter progress study. Ann Rheum Dis 77:348. https:\/\/doi.org\/10.1136\/annrheumdis-2018-eular","journal-title":"Ann Rheum Dis"},{"key":"7695_CR25","unstructured":"Larida B (2015) Autoantibodies against CD74\u00a0\u2013 a new diagnostic marker for spondyloarthritis (SpA) [abstract].\u00a0Arthritis Rheumatol 67 (suppl 10). https:\/\/acrabstracts.org\/abstract\/autoantibodies-against-cd74-a-new-diagnosticmarker-for-spondyloarthritis-spa\/. Accessed 1 July 2025"},{"issue":"4","key":"7695_CR26","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s10067-025-07393-0","volume":"44","author":"A Steimer","year":"2025","unstructured":"Steimer A, G\u00f6tschi A, Witte T, Scherer A, Br\u00e4ndli J, Nissen MJ, M\u00f6ller B, Grosswiler S, Kyburz D, Dan D, Rubbert-Roth A, Adler S, Distler O, Baraliakos X, Ciurea A (2025) Anti-CD74 autoantibodies in axial spondyloarthritis as biomarkers for activity and severity of disease but not for tumour necrosis factor inhibitor retention: data from the Swiss Clinical Quality Management in rheumatic diseases cohort. Clin Rheumatol 44(4):1589\u20131596. https:\/\/doi.org\/10.1007\/s10067-025-07393-0","journal-title":"Clin Rheumatol"},{"issue":"4","key":"7695_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5152\/eurjrheum.2021.20090","volume":"8","author":"S \u00c7olak","year":"2021","unstructured":"\u00c7olak S, Turgay TM, K\u00fc\u00e7\u00fck\u015fahin O, Duman MT, \u00c7etinkaya H, Toruner M (2021) The association of anti-CD74 antibody with spondyloarthropathies. Eur J Rheumatol 8(4):207\u2013210. https:\/\/doi.org\/10.5152\/eurjrheum.2021.20090","journal-title":"Eur J Rheumatol"},{"key":"7695_CR28","doi-asserted-by":"publisher","unstructured":"Kuznetsova DA, Lapin SV, Gaydukova IZ, Rebrov AP, Maslyansky AL (2018)The clinical diagnostic significance of auto antibodies to CD74 at axial spondylarthritis.]. Klin Lab Diagn 63(5):297\u2013301. Russian. https:\/\/doi.org\/10.18821\/0869-2084-2018-63-5-297-301","DOI":"10.18821\/0869-2084-2018-63-5-297-301"},{"key":"7695_CR29","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1136\/annrheumdis-2012-202208","volume":"73","author":"N Baerlecken","year":"2014","unstructured":"Baerlecken N, Nothdorft S (2014) Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis 73:1211\u20131214","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"7695_CR30","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/eji.201948502","volume":"50","author":"TS van Kempen","year":"2020","unstructured":"van Kempen TS, Leijten EFA, Lindenbergh MFS, Nordkamp MO, Driessen C, Lebbink RJ, Baerlecken N, Witte T, Radstake TRDJ, Boes M (2020) Impaired proteolysis by SPPL2a causes CD74 fragment accumulation that can be recognized by anti-CD74 autoantibodies in human ankylosing spondylitis. Eur J Immunol 50(8):1209\u20131219. https:\/\/doi.org\/10.1002\/eji.201948502","journal-title":"Eur J Immunol"},{"issue":"6","key":"7695_CR31","first-page":"1127","volume":"38","author":"T Witte","year":"2020","unstructured":"Witte T, K\u00f6hler M, Georgi J, Schweikhard E, Matthias T, Baerlecken N, Hermann KG, Sieper J, Rudwaleit M, Poddubnyy D (2020) IgA antibodies against CD74 are associated with structural damage in the axial skeleton in patients with axial spondyloarthritis. Clin Exp Rheumatol 38(6):1127\u20131131","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"7695_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.55563\/clinexprheumatol\/lezc69","volume":"38","author":"G Sogkas","year":"2020","unstructured":"Sogkas G, Klose K, Baerlecken N, Schweikhard E, Matthias T, Kniesch K, Schmidt RE, Witte T (2020) CD74 is a T cell antigen in spondyloarthritis. Clin Exp Rheumatol 38(2):195\u2013202. https:\/\/doi.org\/10.55563\/clinexprheumatol\/lezc69","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"7695_CR33","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/art.40175","volume":"69","author":"V Ranganathan","year":"2017","unstructured":"Ranganathan V, Ciccia F, Zeng F, Sari I, Guggino G, Muralitharan J, Gracey E, Haroon N (2017) Macrophage migration inhibitory factor induces inflammation and predicts spinal progression in ankylosing spondylitis. Arthritis Rheumatol 69(9):1796\u20131806. https:\/\/doi.org\/10.1002\/art.40175","journal-title":"Arthritis Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07695-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07695-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07695-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:02:14Z","timestamp":1769763734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07695-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7695"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07695-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the institution's ethics board with permission number 36264MS333\/9\/23 and is in accordance with the Declaration of Helsinki's ethical principles as well as the ethical standards of the Tanta Faculty of Medicine. According to the local ethical commission, informed consent was received from each patient. Every patient file included a code number that incorporated the results of all investigations, ensuring the privacy of all patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publication"}},{"value":"The authors declare no funding and no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}